MicorRNA-195 links long non-coding RNA SEMA3B antisense RNA 1 (head to head) and cyclin D1 to regulate the proliferation of glioblastoma cells

Kaijun Liu\textsuperscript{a,b}, Yan Deng\textsuperscript{a,b}, Yongxia Yang\textsuperscript{a}, Hui Wang\textsuperscript{a}, and Ping Zhou \textsuperscript{a} \\
\textsuperscript{a}Department of Neurosurgery, Shiyan Taihe Hospital (Affiliated Taihe Hospital of Hubei University of Medicine), Shiyan City, PR. China; \textsuperscript{b}Community Health Service Center of Shiyan Economic Development Zone, Shiyan City, PR. China

ABSTRACT

Long non-coding RNA (lncRNA) SEMA3B antisense RNA 1 (head to head) (SEMA3B-AS1) is a recently identified tumor suppressor in gastric cancer. However, its role in glioblastoma (GBM) is unclear. This study was conducted to explore the role of SEMA3B-AS1 in GBM. In this study, the expression of SEMA3B-AS1, cyclin D1 and miR-195 were determined by RT-qPCR. Gene interactions were evaluated by dual-luciferase assay and overexpression experiments. BrdU assay was performed to monitor cell proliferation. We observed downregulation of SEMA3B-AS1 in GBM. The expression of SEMA3B-AS1 was inversely correlated with the expression of cyclin D1 but positively correlated with the expression of miR-195. In GBM cells, overexpression of SEMA3B-AS1 and miR-195 caused reduced expression levels of cyclin D1. MiR-195 inhibitor reduced the effects of overexpression of SEMA3B-AS1 on the expression of cyclin D1. Moreover, overexpression of SEMA3B-AS1 increased the expression levels of miR-195. Cell proliferation data showed that, SEMA3B-AS1 and miR-195 decreased cell proliferation, while overexpression of cyclin D1 increased GBM cell proliferation. In addition, miR-195 inhibitor inhibited the role of overexpression of SEMA3B-AS1 in cancer cell proliferation. Moreover, miR-195 interacted with cyclin D1, but not SEMA3B-AS1. Furthermore, SEMA3B-AS1 decreased the methylation of the promoter region of miR-195. Therefore, we concluded that miR-195 links IncRNA SEMA3B-AS1 and cyclin D1 to regulate the proliferation of GBM cells.

Introduction

Glioma has four subtypes including oligodendro-gliomas, mixed gliomas, ependymomas and astrocytic tumors. Glioblastoma (GBM) is a type of astrocytic tumor that accounts for about 80% of all brain cancer cases [1]. GBM is characterized by its high mortality rate. With treatment, GBM patients can only survive several months [2,3].

ARTICLE HISTORY

Received 21 October 2021
Revised 8 March 2022
Accepted 9 March 2022

KEYWORDS
Glioblastoma; SEMA3B-AS1; cyclin D1; miR-195; proliferation

With the growth of
aging population, the burden of GBM is predicted to be further increased [5].

Various factors affect the occurrence, development and progression of GBM, while genetic and epigenetic factors play central roles [6,7]. Long non-coding RNA (lncRNAs) participate in human cancers by regulating gene expression involved in cancer biology [8-10]. Cyclin D1 promotes cancer development by regulating cell cycle progression [11]. In cancer development, cyclin D1 can be regulated by both lncRNAs [12] and miRNAs [13], which lack protein-coding capacity but affect protein synthesis and the expression of other non-coding genes to regulate cancer progression. In effect, certain lncRNAs and miRNAs are promising targets for cancer therapy [12,13]. LncRNA SEMA3B antisense RNA 1 (head to head) (SEMA3B-AS1) has recently been shown to suppress gastric cancer [14]. Our preliminary microarray data showed that SEMA3B-AS1 was downregulated in GBM and inversely correlated with cyclin D1, which can be targeted by miR-195. Moreover, our microarray data also revealed the positive correlation between SEMA3B-AS1 and miR-195. Therefore, we speculated that SEMA3B-AS1, miR-195 and cyclin D1 may interact with each other to participate in GBM. We then explored the involvement of SEMA3B-AS1 in GBM and analyzed its potential crosstalk with miR-195 and cyclin D1.

**Methods**

**Research subjects**

This study included 66 GBM patients (41 males and 25 females, age range 23 to 64 years old, mean age 44.3 ± 6.1 years old) who were selected from the 144 GBM patients admitted to Shiyan Taihe Hospital (Affiliated Taihe Hospital of Hubei University of Medicine) between June 2014 and September 2018. Patients with recurrent GBM, initiated therapy, other clinical disorders, family history or previous history of malignancies were excluded. All patients with glioblastoma underwent a CT scan, followed by MRI. Pathological diagnosis was performed using tumor tissues resected during surgery. All patients were Han Chinese. PTEN mutation was found in 10 cases, EGFR mutation was found in 12 cases, and TERT mutation was found in 11 cases. All patients were newly diagnosed GBM patients with no initiated therapy. Based on histological findings, all GBM patients were grade IV. This study was approved by the Ethics Committee of the aforementioned hospital. All patients were informed with the whole experimental protocol and the potential publication of the experiment data. All the 66 GBM patients signed the informed consent.

**Tissue collection and confirmation**

Biopsy of tumor (GBM) as well as adjacent (within 2 cm around tumors) non-cancer tissues were collected from each patient. All specimens were confirmed through histopathological tests performed by 3 experienced pathologists. Tissue samples were stored in liquid nitrogen prior to the subsequent experiments.

**Cells and transient transfections**

Human GBM cell lines U87 and U251 (ATCC* HTB14™, ATCC) were used. DMEM medium supplemented with 10% FBS and 100 U/ml penicillin/streptomycin was used to culture cells at 37°C with 5% CO₂. SEMA3B-AS1 and cyclin D1 expression vectors (pcDNA3.1) were constructed by Sangon (Shanghai, China). SEMA3B-AS1 siRNA and NC siRNA were synthesized by Invitrogen (Shanghai, China). MiR-195 mimic and inhibitor as well as negative control (NC) were purchased from Sigma-Aldrich (USA). All transient cell transfections were performed using lipofectamine 2000 transfection reagent (Sigma-Aldrich, USA) to transfet 10 nM vectors, 30 nM miRNA, 30 nM siRNA or 30 nM inhibitor into 10⁵ cells. Transfection with empty pcDNA3.1 vector, negative control miRNA or inhibitor negative control was used as negative control (NC). Cells without transfection were used as the Control (C) cells.

**RT- qPCR**

Ribozol was mixed with the ground tissues (ground in liquid nitrogen) or U87 cells (collected at 24 h after transfection) to isolate total RNAs. After digestion with DNase I, total RNA samples were reverse
transcribed into cDNA using the SSRT III kit (Thermo Fisher Scientific, USA). With cDNA as template, qPCR was then performed to detect the expression of SEMA3B-AS1 and cyclin D1 with 18S rRNA as the endogenous control. miRNAs were also isolated from ground tissues (ground in liquid nitrogen) or U87 cells (collected at 24 h after transfection) using the microRNA Purification Kit (Norgen Biotek Corp, USA). Following the addition of poly (A) tail and reverse transcriptions, qPCRs were performed to analyze the expression of miR-545 with U6 as the endogenous control. PCR reactions were performed for 3 times and Ct values were analyzed using the $2^{-\Delta\Delta Ct}$ method [15]. Primer sequences were 5'-CTCCAAATATCTCAACCTCTC-3' (forward) and 5'-GGGCACGTTCACCAGACTCA-3' (reverse) for SE MA3B-AS1; 5'-GTAACCCGTGAACCCCAT-3' (forward) and 5'-CCATCCAATCGGTAGTAGC-3' (reverse) for 18S rRNA; 5'-CGTCCATGCGGAAG ATC-3' (forward) and 5'-ATGGCCAGCGGGAA GAC-3' (reverse) for cyclin D1; 5'-CTTCGGCAGC ACATATACAAAAAT-3' (forward) and R'sCGCT TCACGAATTTGCGTGCA-3' (reverse) for U6; 5'- TAGCAGCACAGAAATATTG-3' (forward) and poly (T) (reverse) for miR-195.

**Dual-luciferase reporter assay**

Dual-luciferase reporter assay was performed to detect luciferase activity of cells as previously described [16]. Luciferase vectors of SEMA3B-AS1 and cyclin D1 were prepared using pmiRGLO Dual-Luciferase miRNA Target Expression Vector (Promega). Luciferase vector of SEMA3B-AS1 or cyclin D1 was co-transfected with miR-195 mimic into U87 cells. Cells were cultivated in 96-well plates and three replicate wells were set for each experiment. Renilla luciferase activity was measured at 48 h after transfection to normalize luciferase activities. Dual-Luciferase$^\circledR$ Reporter Assay System (Promega) was used to complete all steps.

**BrdU incorporation assay**

BrdU incorporation was used to reflect the proliferation of 6000 cells from each transfection group as previously described [17]. Three biological replicates of cells were treated with BrdU (10 μM) for 24 h. Cells were then fixed for 1 h and peroxidase-coupled anti-BrdU-antibody (Sigma–Aldrich) was used to incubate the cells for 60 min. Following PBS washing, cells were incubated with peroxidase substrate for 1 h. Finally, OD values at 450 nm were measured using the BioTek Epoch 2 Microplate Spectrophotometer.

**Methylation-specific PCR**

Genomic DNA was isolated from cells transfected with empty pcDNA3.1 vector or SEMA3B-AS1 expression vector using Wizard$^\circledR$ Genomic DNA Purification Kit (Promega). Bisulfite modification was performed using EZ DNA Methylation-Gold Kit (Zymo Research). Methyl primer express v1.0. software (Applied Biosystems) was used to design primers to amplify the promoter region (from position –125 to position –1568) of miR-195.

**Western-blot analysis**

U87 cells (10$^5$ cells, collected at 24 h after transfection) were mixed with cell lysis buffer solution (Beyotime, Jiangsu, China) to extract total proteins. Total proteins were denatured and separated with 10% SDS-PAGE gel electrophoresis with 30 μg protein per lane, followed by transferring to PVDF membranes. After blocking with 5% non-fate milk, the membranes were incubated with primary antibodies GAPDH (1:2,000, ab37168, Abcam) and cyclin D1 (1:2,000, ab226977, Abcam) at 4°C overnight. The next day, IgG-HRP secondary antibody (1:1,000, MBS435036, Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd) was used to incubate with the membranes at 22°C for 2 h. Finally, Enhanced chemiluminescence (Pierce SuperSignal, Thermo Scientific) was used for signal production.

**Statistical process**

GraphPad Prism 6 was used for data analyses. All experiments were repeated for 3 times to calculate the mean values. Paired t test was used to compare paired tissues. ANOVA Tukey’s test was used to compare multiple groups. Linear regression was used to analyze correlations. Statistically significant level was $p<0.05$. 
Results

The expression of SEMA3B-AS1 in GBM

The 66 patients were subjected to mutation analysis. According to NGS mutational analysis (Illumina MiSeq System) results, PTEN mutation was found in 10 cases, EGFR mutation was found in 12 cases and TERT mutation was found in 11 cases, and the rest 33 patients showed no mutation. To explore the potential involvement of SEMA3B-AS1 in GBM, the expression of SEMA3B-AS1 in GBM and non-cancer tissues from GBM patients was detected by performing RT-qPCR. In comparison to non-cancer tissues, GBM tissues exhibited significantly lower expression levels of SEMA3B-AS1 (Figure 1, \( p < 0.05 \)). Therefore, the downregulation of SEMA3B-AS1 may participate in GBM.

The expression of SEMA3B-AS1 in GBM tissues was significantly correlated with the expression of cyclin D1 and miR-195

The expression of cyclin D1 and miR-195 in paired GBM and non-cancer tissues from GBM patients was also detected by performing RT-qPCR. Compared to non-cancer tissues, cyclin D1 was significantly upregulated in GBM tissues (3.5-fold, data not shown), and miR-195 was significantly downregulated in GBM tissues (0.28-fold, data not shown). Correlations among SEMA3B-AS1, cyclin D1 and miR-195 were analyzed by performing linear regression. The expression of SEMA3B-AS1 was inversely and significantly correlated with the expression of cyclin D1 (Figure 2a), but positively and significantly correlated with the expression of miR-195 (Figure 2b). It is worth noting that our preliminary microarray data showed that SEMA3B-AS1 was downregulated in GBM (Supplemental Fig. 1A, \( p < 0.01 \)) and inversely correlated with cyclin D1 (Supplemental Fig. 1B). Moreover, our preliminary microarray data also revealed the positive correlation between SEMA3B-AS1 and miR-195 (Supplemental Fig. 1B). Therefore, SEMA3B-AS1, cyclin D1 and miR-195 may interact with each other to participate in GBM.

SEMA3B-AS1 regulated cyclin D1 through miR-195

To explore the relationship among SEMA3B-AS1, cyclin D1 and miR-195, SEMA3B-AS1 or cyclin D1 expression vector, miR-195 mimic or miR-195 inhibitor was transfected into U87 cells. Compared to C and NC, the expression of SEMA3B-AS1, miR-195 and cyclin D1 were significantly altered at 24 h after transfection (Figure 3a, \( p < 0.05 \)), indicating successful transfections. Moreover, compared to C and NC, overexpression of SEMA3B-AS1 also increased the expression levels of miR-195, while overexpression of miR-195 did not affect the expression of SEMA3B-AS1 (Figure 3b, \( p < 0.05 \)). Overexpression of SEMA3B-AS1 and miR-195 reduced the expression levels of cyclin D1, and miR-195 inhibitor attenuated the effects of overexpression of SEMA3B-AS1 on cyclin D1 expression (Figure 3c, \( p < 0.05 \)). The interaction between SEMA3B-AS1 and miR-195, and the interaction between miR-195 and cyclin D1 was explored by performing Dual-luciferase reporter assay. It was observed that miR-195 did not alter the luciferase activity of SEMA3B-AS1 vector (Supplemental Fig. 2A), but decreased the luciferase activity of SEMA3B-AS1 vector (Supplemental Fig. 2B, \( p < 0.01 \)).
SEMA3B-AS1 inhibited U87 cell proliferation through cyclin D1 and miR-195 in both U87 and U251 cells

Cell proliferation contributes to the progression of GBM. To this end, the role of SEMA3B-AS1, cyclin D1 and miR-195 in regulating U87 cell proliferation was analyzed by BrdU assay. The results showed that overexpression of SEMA3B-AS1 and miR-195 decreased cell proliferation, while silencing of SEMA3B-AS1 and overexpression of cyclin D1 increased the proliferation rate of GBM cells. In addition, miR-195 inhibitor attenuated the effects of overexpression of SEMA3B-AS1 on cancer cell proliferation (Figure 4). Therefore, SEMA3B-AS1 may inhibit GBM cell proliferation by downregulating cyclin D1 through...
miR-195. The same experiment was also performed on U251 cells and similar results were obtained (Supplemental Fig. 3).

**SEMA3B-AS1 increased the methylation of miR-195 promoter**

MSP was performed to analyze the role of SEMA3B-AS1 in regulating the methylation of miR-195 promoter. Compared to cells transfected with empty pcDNA3.1 vector, cells transfected with SEMA3B-AS1 vector showed decreased methylation of miR-195 promoter (Figure 5). Therefore, SEMA3B-AS1 may upregulate miR-195 by reducing the methylation of its promoter.

**Discussion**

Treatment of GBM always needs novel therapeutic targets. In the present study we investigated the role of SEMA3B-AS1 in GBM and found that SEMA3B-AS1 is a tumor suppressor in GBM. In addition, we also characterized the involvement of the SEMA3B-AS1/miR-195/cyclin D1 axis in the proliferation of GBM cells.

Inhibition of cancer cell proliferation is always essential for clinical treatment of cancer. D cyclins play a pivotal role in cell cycle progression by forming complex with CDK4 or CDK6 to phosphorylate the retinoblastoma and drive the transition from G1 to S phase, thereby promoting cell proliferation [18]. Cyclin D1 is member of D cyclins that is usually upregulated in cancers including GBM [19,20]. A recent study reported that cyclin D1 is a direct target of miR-195 in glioma [13]. The present study also observed the downregulated expression of cyclin D1 in GBM cells after overexpression of miR-195.

LncRNAs may have similar functionalities in different types of cancer. For example, IncRNA HOTAIR shows similar functions in regulating cancer cell behaviors in different types of cancer [21]. SEMA3B-AS1 was downregulated in gastric cardia adenocarcinoma and overexpression of SEMA3B-AS1 resulted in inhibited cancer cell proliferation. Similarly, we also found the downregulation of SEMA3B-AS1 in GBM and the suppressed proliferation of GBM cells after overexpression of SEMA3B-AS1. However, our study did not detect the expression of SEMA3B-AS1 in patients’ plasma (data not shown). Circulating lncRNAs released into blood from the site of synthesis have been widely used to predict cancer development [22], while SEMA3B-AS1 may be
not a good option possibly due to its low level in blood.

The interactions between lncRNAs and miRNAs have been extensively investigated in previous studies [23]. LncRNAs may serve as the sponge of miRNAs to inhibit their roles [24]. However, the mechanism of the upregulation of miRNAs by lncRNAs is largely unknown. The present study showed that SEMA3B-AS1 was an upstream positive regulator of miR-195, and the upregulation of miR-195 by SEMA3B-AS1 is involved in the regulation of cyclin D1 and GBM cell proliferation. Interestingly, we observed that SEMA3B-AS1 can decrease the methylation of miR-195 promoter in GBM cells. Therefore, SEMA3B-AS1 may upregulate miR-195 in GBM by reducing the methylation of its promoter. Our study characterized a novel SEMA3B-AS1/miR-195/cyclin D1 axis involved in GBM, while the upregulation of miR-195 by SEMA3B-AS1 still needs to be further investigated. A recent study reported that IncRNA RUNX1-IT1 can also sponge miR-195 to upregulate cyclin D1 in glioblastoma, thereby promoting cell proliferation [25]. Therefore, miR-195 in GBM may be sponged by multiple lncRNAs.

**Conclusion**

In conclusion, SEMA3B-AS1 is downregulated in GBM and overexpression of SEMA3B-AS1 can downregulate cyclin D1 and suppress GBM cell proliferation possibly through miR-195. With the increased understanding of the molecular mechanism of GBM [26,27], lncRNAs are expected to be targeted to treat GBM.

**Abbreviations**

Glioblastoma (GBM) long non-coding RNAs (lncRNAs, > 200 nt)

**Acknowledgements**

Not applicable

**Authors contributions**

KL, YD, PZ conceived this study. KL and YD finished the experiment. YY and HW analyzed data and helped interpreting results. KL written the manuscript. PZ revised the manuscript.

**Availability of data and materials**

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

**Consent for publication**

Not applicable

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

The author(s) reported there is no funding associated with the work featured in this article.

**Ethics approval and consent to participate**

The present study was approved by the Ethics Committee of Shiyian Taihe hospital (Affiliated Taihe Hospital of Hubei University of Medicine). The research has been carried out in accordance with the World Medical Association Declaration of Helsinki. All patients and healthy volunteers provided written informed consent prior to their inclusion within the study.

**ORCID**

Ping Zhou https://orcid.org/0000-0002-9552-1102

**References**

[1] Rock K, McArdle O, Forde P, et al. A clinical review of treatment outcomes in glioblastoma multiforme—the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival? Br J Radiol. 2012;85(1017):e729–e733.

[2] Aldape K, Zadeh G, Mansouri S, et al. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):829–848.

[3] Delgado-Lopez PD, Corrales-Garcia EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18(11):1062–1071.

[4] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.
[5] Brandes AA, Vastola F, Basso U, et al. A prospective study on glioblastoma in the elderly. Cancer. 2003;97(3):657–662.

[6] Li QI, Cai JQ, Liu CY. Evolving molecular genetics of glioblastoma. Chin Med J (Engl). 2016;129(4):464–471.

[7] Liu A, Hou C, Chen H, et al. Genetics and epigenetics of glioblastoma: applications and overall incidence of IDH1 mutation. Front Oncol. 2016;6:16.

[8] Han L, Zhang K, Shi Z, et al. LncRNA profile of glioblastoma reveals the potential role of lncRNAs in contributing to glioblastoma pathogenesis. Int J Oncol. 2012;40(6):2004–2012.

[9] Prensner JR, Chinaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov. 2011;1(5):391–407.

[10] Evans JR, Feng FY, Chinaiyan AM. The bright side of dark matter: lncRNAs in cancer. J Clin Invest. 2016;126(8):2775–2782.

[11] Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl). 2016;94(12):1313–1326.

[12] Liu Y, Wang LL, Chen S, et al. LncRNA ABHD11-AS1 promotes the development of endometrial carcinoma by targeting cyclin D1. J Cell Mol Med. 2018;22(8):3955–3964.

[13] Hui W, Yuntao L, Lun L, et al. MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1. PloS One. 2013;40(1):e54932.

[14] Guo W, Liang X, Liu L, et al. MiR-6872 host gene SEMA3B and its antisense lncRNA SEMA3B-AS1 function synergistically to suppress gastric cardia adenocarcinoma progression. Gastric Cancer 2019 1–18 doi: 10.1007/s10120-018-0868-0

[15] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408.

[16] McNabb DS, Reed R, Marciniak RA. Dual luciferase assay system for rapid assessment of gene expression in Saccharomyces cerevisiae. Eukaryot Cell. 2005;4(9):1539–1549.

[17] Muskheilvili L, Latendresse JR, Kodell RL, et al. Evaluation of cell proliferation in rat tissues with BrdU, PCNA, Ki-67 (MIB-5) immunohistochemistry and in situ hybridization for histone mRNA. J Histochem Cytochem. 2003;51(12):1681–1688.

[18] Kato JY, Sherr CJ. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc Natl Acad Sci USA. 1993;90:11513–12115.

[19] Shan YS, Hsu HP, Lai MD, et al. Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer. Oncol Lett. 2017;14(4):4517–4526.

[20] Li X, Gong X, Chen J, et al. miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2. Biochem Biophys Res Commun. 2015;460(3):670–677.

[21] Bhan A, Mandal SS. LncRNA HOTAIR: a master regulator of chromatin dynamics and cancer. Biochim Biophys Acta. 2015;1856(1):151–164.

[22] Qi P, Zhou X, Du X. Circulating long non-coding RNAs in cancer: current status and future perspectives. Mol Cancer. 2016;15(1):39.

[23] Pasarkevopoulou MD, Hatzigeorgiou AG. Analyzing miRNA–lncRNA interactions(M)/Long Non-Coding RNAs. New York(NY): Humana Press; 2016. p. 271–286.

[24] Thomson DW, Dingere ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272–282.

[25] Wu Z. MiR-195 connects lncRNA RUNX1-IT1 and cyclin D1 to regulate the proliferation of glioblastoma cells. Int J Neurosci. 2021;1–6. doi:10.1080/00207454.2021.1881090

[26] Wang J, Xia X, Tao X, et al. Knockdown of carbohydrate sulfotransferase 12 decreases the proliferation and mobility of glioblastoma cells via the WNT/β-catenin pathway. Bioengineering. 2021;12(1):3934–3946.

[27] Liu L, Xiao S, Wang Y, et al. Identification of a novel circular RNA circZNF652/miR-486-5p/SERPINE1 signaling cascade that regulates cancer aggressiveness in glioblastoma (GBM). Bioengineered. 2022;13(1):1411–1423.